POMBILITI

This brand name is authorized in Austria, France, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug POMBILITI contains one active pharmaceutical ingredient (API):

1	Cipaglucosidase alfa UNII 4SED7F4BSG - CIPAGLUCOSIDASE ALFA
	Sipaglucosidase alfa is intended to replace the endogenous enzyme acid-alpha-glucosidase (GAA) that breaks down glycogen to glucose in the lysosome and is absent or impaired in Pompe disease. Sipaglucosidase alfa exerts enzymatic activity in the breakdown of glycogen and the reduction of intramuscular glycogen, as well as the amelioration of tissue damage.
	Read more about Cipaglucosidase alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
POMBILITI Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB23		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	1221714001
FR	Base de données publique des médicaments	64427538
LT	Valstybinė vaistų kontrolės tarnyba	1096835, 1096836, 1096837